DUBLIN, Feb. 1, 2021 /PRNewswire/ — The « Cold Milling Machine – Global Market Outlook (2019-2027) » report has been added to ResearchAndMarkets.com’s offering.
Global Cold Milling Machine market accounted for $1.10 billion in 2019 and is expected to reach $1.75 billion by 2027 growing at a CAGR of 6.0% during the forecast period. Some of the key factors propelling the Growth of the market are growing focus towards the development of new roads, rising demand for asphalt milling, and rise in the number of vehicles on the road. However, the higher initial cost is the restraining factor for the growth of the market.The cold milling machine is a piece of heavy equipment used to remove old asphalt pavements and surfaces from roadways, to obtain an even surface. The machine’s revolving cutting head cuts into the pavement at a predetermined depth and cross slope and removes the reclaimed asphalt pavement (RAP). This machine is equipped with a conveyor which deposits the RAP into a transport truck, or the RAP can be left in place to be removed later or used in recycling.By application, the highway segment is expected to grow at a significant market share during the forecast period owing to the growing road construction sector which increases the demand for asphalt pavement.Based on geography, Asia Pacific is anticipated to hold considerable market share during the forecast period which is attributed to the increasing urbanization in the region which leads to investment and government spending.Some of the key players in Cold Milling Machine Market include John Deere, Caterpillar, Atlas Copco, Bomag, Sany Group, SCMC, RoadTec, Huatong Kinetics, XCMG, XGMA, Xi’an Hongda, XRMC, Dingsheng, CMI, Wirtgen, LiuGong, and Zoomlion.What the report offers:
Competitive landscaping mapping the key common trends Company Profiling with detailed strategies, financials, and recent developments
Key Topics Covered: 1 Executive Summary2 Preface2.1 Abstract2.2 Stake Holders2.3 Research Scope2.4 Research Methodology2.5 Research Sources3 Market Trend Analysis3.1 Introduction3.2 Drivers3.3 Restraints3.4 Opportunities3.5 Threats3.6 Application Analysis3.7 Emerging Markets3.8 Impact of COVID-194 Porters Five Forces Analysis4.1 Bargaining Power of Suppliers4.2 Bargaining Power of Buyers4.3 Threat of Substitutes4.4 Threat of New Entrants4.5 Competitive Rivalry5 Global Cold Milling Machine Market, By Size5.1 Introduction5.2 Large Cold Milling Machine5.3 Medium Cold Milling Machine5.4 Small Cold Milling Machine6 Global Cold Milling Machine Market, By Engine Power6.1 Introduction6.2 Above 300 kW6.3 155 kW-300 kW6.4 Less Than 155 kW7 Global Cold Milling Machine Market, By Type7.1 Introduction7.2 Crawler Type7.3 Wheel Type8 Global Cold Milling Machine Market, By Sales Channel8.1 Introduction8.2 Distribution Channel8.3 Direct Channel9 Global Cold Milling Machine Market, By Application9.1 Introduction9.2 Airport9.3 Storage Yard9.4 Highway9.4.1 Asphalt Road9.4.2 Concrete Road10 Global Cold Milling Machine Market, By Milling Width10.1 Introduction10.2 Above 2.0 m10.3 1.3 – 2.0 m10.4 0-1.3 m11 Global Cold Milling Machine Market, By Geography11.1 Introduction11.2 North America11.2.1 US11.2.2 Canada11.2.3 Mexico11.3 Europe11.3.1 Germany11.3.2 UK11.3.3 Italy11.3.4 France11.3.5 Spain11.3.6 Rest of Europe11.4 Asia-Pacific11.4.1 Japan11.4.2 China11.4.3 India11.4.4 Australia11.4.5 New Zealand11.4.6 South Korea11.4.7 Rest of Asia-Pacific11.5 South America11.5.1 Argentina11.5.2 Brazil11.5.3 Chile11.5.4 Rest of South America11.6 Middle East & Africa11.6.1 Saudi Arabia11.6.2 UAE11.6.3 Qatar11.6.4 South Africa11.6.5 Rest of Middle East & Africa12 Key Developments12.1 Agreements, Partnerships, Collaborations and Joint Ventures12.2 Acquisitions & Mergers12.3 New Product Launches12.4 Expansions12.5 Other Key Strategies13 Company Profiling13.1 John Deere13.2 Caterpillar13.3 Atlas Copco13.4 Bomag13.5 Sany Group13.6 SCMC13.7 RoadTec13.8 Huatong Kinetics13.9 XCMG13.10 XGMA13.11 Xi’an Hongda13.12 XRMC13.13 Dingsheng13.14 CMI13.15 Wirtgen13.16 LiuGong13.17 ZoomlionFor more information about this report visit https://www.researchandmarkets.com/r/lwweoo
Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call 353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): 353-1-481-1716
Here’s a game many would like to play how to make a billion bucks in a month? And nine investors just pulled it off with GameStop stock.
(Bloomberg) — BioCryst Pharmaceuticals Inc. blew past a five-year high as Reddit investors rallied around a call to start a “#BioWar” on the bears behind a heavily-shorted biotech that develops rare disease drugs.The stock, which recently ended development of an experimental therapy for Covid-19, rallied to close 39% higher on Monday after a poster on Reddit’s WallStreetBets forum called it “the most undervalued stock in the market” while another said a brewing #BioWar was “about sticking it to the shorts in a massive way.”Biotechs with little to no revenue have long been the focus of short bets on Wall Street and could emerge as a new focal point for small-time investors railing against elite hedge funds. But the battleground is an already crowded arena with hedge funds positioned on both sides.Indeed, BioCryst is a short target with about 17% of float, or $259 million, sold short, according to financial analytics firm S3 Partners. But it’s also a hedge fund pick held by the likes of Citadel, the well-known biotech outfit Baker Bros. Advisors LP, and activist investor Alex Denner’s Sarissa Capital Management.Before Monday’s rally, shares of BioCryst had already shrugged off the scuttling of a Covid-19 trial supported by the National Institutes of Health. The company is expected to generate less than $31 million in revenue for all of 2020.Novavax Inc., another heavily-shorted biotech, has also garnered interest across chat forums, which could benefit funds like RA Capital Management and Perceptive Advisors, which hold stakes in the company. The stock has more than doubled in the past few trading days, albeit on late-stage positive results for its Covid-19 vaccine candidate. The short position on Novavax stands at $1.5 billion, according to S3.Throughout the pandemic, biotechs racing to find the next Covid-19 treatment or vaccine have captured the imagination of retail investors. Dynavax Technologies Corp. added another $436 million in market value on Monday on news it had both initiated a mid-stage Covid vaccine study with one partner and that the U.K. had exercised an option to order more inoculations from another Dynavax partner using the company’s adjuvant.Inovio Pharmaceuticals Inc. also soared Monday after Twitter users jumped on a filing over BlackRock Inc.’s stake in the company. One tweet said BlackRock had doubled its position, although Bloomberg data show the stake is virtually unchanged.Meanwhile, the motivations behind Monday’s 131% rally in Healthier Choices Management Corp. powered by Reddit was unclear as Twitter users said it was an opportunity to send hedge funds “on the run.” Short interest in the sub-penny stock, which makes vaping products and operates health food stores in Florida, appears non-existent however. The micro-cap’s largest holders were its management team.(Updates to add Covid-19 stock plays as well as Healthier Choices trading details)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
DraftKings is one of the top IPO stocks to watch, as gambling legalization gains steam. Here is what the fundamentals and technical analysis say about buying DKNG stock now.
Let’s talk portfolio defense. After last week’s social flash mob market manipulation, that’s a topic that should not be ignored. Now, this is not to say that the markets are collapsing. After 2% losses to close out last week’s Friday session, this week’s trading kicked off with a positive tone, as the S&P 500 rose 1.5% and the Nasdaq climbed 2.5%. The underlying bullish factors – a more stable political scene, steadily progressing COVID vaccination programs – are still in play, even if they are not quite as strong as investors had hoped. While increased volatility could stay with us for a while, it’s time to consider defensive stocks. And that will bring us to dividends. By providing a steady income stream, no matter what the market conditions, a reliable dividend stock provides a pad for your investment portfolio when the share stop appreciating. With this in mind, we’ve used the TipRanks database to pull up three dividend stocks yielding 8%. That’s not all they offer, however. Each of these stocks has scored enough praise from the Street to earn a “Strong Buy” consensus rating. New Residential Investment (NRZ) We’ll start by looking into the REIT sector, real estate investment trusts. These companies have long been known for dividends that are both high-yield and reliable – as a result of company compliance with tax rules, that require REITs to return a certain percentage of profits directly to shareholders. NRZ, a mid-size company with a market cap of $3.9 billion, holds a diverse portfolio of residential mortgages, original loans, and mortgage loan servicing rights. The company is based in New York City. NRZ holds a $20 billion investment portfolio, which has yielded $3.4 billion in dividends since the company’s inception. The portfolio has proven resilient in the face of the corona crisis, and after a difficult first quarter last year, NRZ saw rising gains in Q2 and Q3. The third quarter, the last reported, showed GAAP income of $77 million, or 19 cents per share. While down year-over-year, this EPS was a strong turnaround from the 21-cent loss reported in the prior quarter. The rising income has put NRZ in a position to increase the dividend. The Q3 payment was 15 cents per common share; the Q4 dividend was bumped up to 20 cents per common share. At this rate, the dividend annualizes to 80 cents and yields an impressive 8.5%. In another move to return profits to investors, the company announced in November that it had approved $100 million in stock repurchases. BTIG analyst Eric Hagen is impressed with New Residential – especially by the company’s sound balance sheet and liquidity. “[We] like the opportunity to potentially build some capital through retained earnings while maintaining a competitive payout. We think the dividend increase highlights the strengthening liquidity position the company sees itself having right now… we expect NRZ has been able to release capital as it’s sourced roughly $1 billion of securitized debt for its MSR portfolio through two separate deals since September,” Hagen opined. In line with his comments, Hagen rates NRZ a Buy, and his $11 price target implies an upside of 17% for the year ahead. (To watch Hagen’s track record, click here) It’s not often that the analysts all agree on a stock, so when it does happen, take note. NRZ’s Strong Buy consensus rating is based on a unanimous 7 Buys. The stock’s $11.25 average price target suggests ~20% upside from the current share price of $9.44. (See NRZ stock analysis on TipRanks) Saratoga Investment Corporation (SAR) With the next stock, we move to the investment management sector. Saratoga specializes in mid-market debt, appreciation, and equity investments, and holds over $546 million in assets under management. Saratoga’s portfolio is wide ranging, and includes industrials, software, waste disposal, and home security, among others. Saratoga saw a slow – but steady – rebound from the corona crisis. The company’s revenues fell in 1Q20, and have been slowly increasing since. The fiscal Q3 report, released early in January, showed $14.3 million at the top line. In pre-tax adjusted terms, Saratoga’s net investment income of 50 cents per share beat the 47-cent forecast by 6%. They say that slow and steady wins the race, and Saratoga has shown investors a generally steady hand over the past year. The stock has rebounded 163% from its post-corona crash low last March. And the dividend, which the company cut back in CYQ2, has been raised twice since then. The current dividend, at 42 cents per common share, was declared last month for payment on February 10. The annualized payment of $1.68 gives a yield of 8.1%. Analyst Mickey Schleien, of Ladenburg Thalmann, takes a bullish view of Saratoga, writing, “We believe SAR’s portfolio is relatively defensive with a focus on software, IT services, education services, and the CLO… SAR’s CLO continues to be current and performing, and the company is seeking to refinance/upsize it which we believe could provide upside to our forecast. » The analyst continued, « Our model anticipates SAR employing cash and SBA debentures to fund net portfolio growth. We believe the Board will continue to increase the dividend considering the portfolio’s performance, the existence of undistributed taxable income, and the economic benefit of the Covid-19 vaccination program.” To this end, Schleien rates SAR a Buy along with a $25 price target. This figure implies a 20% upside from current levels. (To watch Schleien’s track record, click here) Wall Street’s analysts agree with Schleien on this stock – the 3 other reviews on record are Buys, and the analyst consensus rating is a Strong Buy. Saratoga’s shares are trading for $20.87, and carry an average price target of $25.50, suggesting an upside of 22% for the next 12 months. (See SAR stock analysis on TipRanks) Hercules Capital (HTGC) Last but not least is Hercules Capital, a venture capital company. Hercules offers financing support to small, early-stage client companies with scientific bent; Hercules’ clients are in life sciences, technology, and financial SaaS. Since getting started in 2003, Hercules has invested over $11 billion in more than 500 companies. The quality of Hercules’ portfolio is clear from the company’s recent performance. The stock has bounced back fully from the corona crisis of last winter, rebounding 140% from its low point reached last April. Earnings have also recovered; for the first nine months of 2020, HTGC posted net investment income of $115 million, or 11% higher than the same period of 2019. For dividend investors, the key point here is that the net investment income covered the distribution – in fact, it totaled 106% of the base distribution payout. The company was confident enough to boost the distribution with a 2-cent supplemental payment. The combined payout gives a $1.28 annualized payment per common share, and a yield of 8.7%. In another sign of confidence, Hercules completed a $100 million investment grade bond offering in November, raising capital for debt pay-downs, new investments, and corporate purposes. The bonds were offered in two tranches, each of $50 million, and the notes are due in March of 2026. Covering the stock for Piper Sandler, analyst Crispin Love sees plenty to love in HTGC. “We continue to believe that HTGC’s focus on fast growing technology and life sciences companies sets the company up well in the current environment. In addition, Hercules is not dependent on a COVID recovery as it does not have investments in « at-risk » sectors. Hercules also has a strong liquidity position, which should allow the company to act quickly when it finds attractive investment opportunities,” Love commented. All of the above convinced Love to rate HTGC an Outperform (i.e. Buy). In addition to the call, he set a $16 price target, suggesting 9% upside potential. (To watch Love’s track record, click here) Recent share appreciation has pushed Hercules’ stock right up to the average price target of $15.21, leaving just ~4% upside from the trading price of $14.67. Wall Street doesn’t seem to mind, however, as the analyst consensus rating is a unanimous Strong Buy, based on 6 recent Buy-side reviews. (See HTGC stock analysis on TipRanks) To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
GameStop shares were down double digit percentages by mid-session on Monday, following a massive short squeeze last month fueled by retail investors on Reddit’s WalStreetBets forum.
Alibaba (BABA) will be reporting earnings on Tuesday before the opening bell. The e-commerce giant is expected to show a boost from its recent 11/11 shopping event. However investors will be watching for any commentary on recent regulatory concerns in China.
Inovio Pharmaceuticals surged Monday on a Reddit call to action and after investment firm BlackRock upped its stake in the biotech company. INO stock soared to a five-month high.
Electric vehicle maker Faraday Future has big goals for the next five years, CEO Carsten Breitfeld explains to Yahoo Finance.
(Bloomberg) — Carson Block, the activist short-seller famous for targeting Chinese frauds, recognizes familiar behavior in the rally of shares such as GameStop Corp. To him, the parabolic moves look less like the product of Reddit-driven retail orders than a short squeeze by hedge funds targeting other hedge funds.“I’ve wondered, is there coordination with these hedge funds?” Block said in an interview on Bloomberg Television. “What constitutes coordination? Did they cross the line? That could be interesting.”For the moment, it’s an unproven theory. But if Block is right, what seemed like a history-making retail uprising last week was just as much a convenient smokescreen for internecine hedge-fund warfare.The list of casualties in that fight is growing from the severely wounded, such as Melvin Capital Management and Maplelane Capital, to include funds run by firms ranging from David Einhorn’s Greenlight Capital to Renaissance Technologies. What’s not clear yet is who profited on the other side.Block said his firm, Muddy Waters Capital, was the victim of what he thinks was a short squeeze by hedge funds in shares of GSX Techedu Inc. in the weeks leading up to the GameStop frenzy. As a result of that and similar situations, he had to hire a full-time trader to monitor the stock-options markets and adjust positions to more actively manage risk.“It’s a trading game, it’s flows-driven, it’s technical,” he said. “We’re going to do what we need to do to survive.”Unlike many short-sellers, Block is decidedly public with the names of companies he believes are scams and which he’s betting against. He typically publishes the research underpinning his short thesis and makes it available on Twitter. More recently, he started releasing videos on zer0es.tv.As he sees it, that effort to expose wrongdoing has a “social utility” and should set him apart from the short-sellers under attack on Reddit. He scoffs at the suggestion that he’s part of a Wall Street establishment. If he were such an insider, he asked, why would Goldman Sachs Group Inc. and Credit Suisse Group AG have turned down his business?“When we get tagged as establishment, you can’t be more inaccurate than that,” he said. “It’s almost funny if it weren’t for the fact that I now have all these people trying to troll me.”What Block agrees with is the growing sense that financial markets are overvalued and predominantly small investors will be hurt when the bubble finally bursts. He faults the Federal Reserve for pumping in too much liquidity, allowing for too much credit extension and too much leverage.“We need a combination of monetary and fiscal policy that makes sense or else we’re just stuck in this building a bigger powder keg to explode again,” he said. “It always transfers wealth from the many to the few.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
General Electric Company (NYSE: GE) shares traded slightly higher on Monday after one Wall Street analyst performed a deep dive into the company’s free cash flow outlook. The GE Analyst: Bank of America analyst Andrew Obin reiterated his Buy rating for GE and raised his price target from $13 to $14. See also: Buy Bank of America Stock The GE Thesis: Last week, GE shares jumped after the company reported a better-than-expected $4.37 billion in fourth-quarter industrial free cash flow and guided for between $2.5 billion and $4.5 billion in industrial FCF in 2021. On Monday, Obin said GE’s 3% year-over-year drop in orders in the fourth quarter was also a pleasant surprise given orders dropped 28% in the previous quarter. The $3.5 billion midpoint of GE’s 2021 industrial FCF guidance was also slightly above Bank of America’s target of $3.3 billion. Obin said investors don’t seem to fully appreciate GE’s multi-year effort to reduce factoring, which was a $3.2 billion outflow in 2020. That process is now coming to an end and Obin said investors can expect working capital levels to begin to normalize. Related Link: ,000, 5 Years Later: How Much Would General Electric Stock Be Worth? Obin understands the caution toward GE given the uncertain economic outlook and the company’s rough recent track record, but he believes the company is being overly cautious with its 2021 Aviation revenue guidance. In the meantime, Obin says GE has plenty of financial flexibility in the near-term, and could actually benefit from rising interest rates. Rising rates would help reduce GE’s $25.5 billion in pension liabilities and GE Capital’s $21.3 billion in long-term care liabilities. “Higher discount rates would lower the value of these long-lived liabilities,” Obin said. Benzinga’s Take: GE appears to have stopped the bleeding by aggressively addressing its liquidity and balance sheet issues, and it has implemented a long-term turnaround plan. However, Obin is forecasting just 62 cents in 2023 earnings per share, suggesting GE is already trading at 17.2 times 2023 earnings even if the company hits Obins growth targets over the next two years. Photo credit: Momoneymoproblemz, via Wikimedia Commons Latest Ratings for GE DateFirmActionFromTo Jan 2021Morgan StanleyMaintainsOverweight Dec 2020DZ BankUpgradesSellHold Dec 2020Morgan StanleyMaintainsOverweight View More Analyst Ratings for GE View the Latest Analyst Ratings See more from BenzingaClick here for options trades from Benzinga,000, 5 Years Later: How Much Would General Electric Stock Be Worth?© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Last week, members of the Reddit forum WallStreetBets were able to pull off a short squeeze for the history books by banding together to take on hedge funds betting against GameStop Corp. (NYSE: GME). Targeting GameStop worked well for the Reddit community because GameStop had very high short interest — over 130% at the time — and has a relatively small float of 51 million. However, the short squeeze was big trouble for Melvin Capital, which was forced to close out its entire GameStop short position for a loss. Afterward Melvin Capital required Citadel and Point72 to inject $3 billion into its fund to bolster its finances. The retail trading community is targeting stocks with the highest percentage of short interest to force institutions to cover their positions, which helps drive the share price dramatically higher. Small retail investors, large hedge funds and financial institutions may be wondering what stock they’ll successfully target next. Related Link: A Short Seller Joins Benzinga’s ‘Power Hour’ To Talk GameStop. The Rest Is History Below are the next 10 most heavily shorted stocks on the Russell 3000 as of Jan. 29, 2021: Accelerate Diagnostics Inc. (NASDAQ: AXDX): Market cap of $600 million with 31.03 total share float and 45% short. Academy Sports and Outdoors Inc (NASDAQ: ASO): Market cap of $1.9 billion with 21.07 million total share float and 45% short. AMC Entertainment Holdings (NYSE: AMC): Market cap of $2 billion with 56.56 million total float and 58% short. Bed Bath & Beyond (NYSE: BBBY): Market cap of $4.3 billion with 230.80 million total float and 63% short. Ligand Pharmaceuticals Inc. (NASDAQ: LGND): Market cap of $3 billion with 15.34 million total float and 65% short. Macerich Co (NASDAQ: MAC): Market cap of $2.3 billion with 137.99 total share float and 57% short. National Beverage Corp (NASDAQ: FIZZ): Market cap of $7.1 billion with 11.64 million total float and 63% short. SunPower Corporation (NASDAQ: SPWR): Market cap of $9.2 billion with 80.91 million total float and 57% short. Tanger Factory Outlet Centers Inc. (NYSE: SKT): Market cap of $1.4 billion with 90.15 total share float and 57% short. Tootsie Roll Industries, Inc. (NYSE: TR): Market cap of $2.6 billion with 16.11 million share float and 46% short. (Photo by Giorgio Trovato on Unsplash) See more from BenzingaClick here for options trades from BenzingaVirgin Galactic Announces Date For New Test Flight Of SpaceShipTwo UnityFord, Google Partner On Android-Connected Vehicles© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Nio and Xpeng posted strong January sales that suggest no pause in China’s electric-vehicle market after 2020’s boom.
If you invested in Tesla Inc (NASDAQ: TSLA) one year ago, you would be up by roughly 600%. The growth in electric vehicles isn’t limited to this one stock: with the Global X Autonomous & Electric Vehicles ETF (NYSE: DRIV) being up roughly 75%. Here are three more companies to look into if you’re enjoying your position in Tesla: Nio Inc (NYSE: NIO) is often touted as the “Tesla of China.” The company operates in China’s premium electric vehicle market. It designs and jointly manufactures, and sells smart and connected premium electric vehicles, driving innovations in next-generation technologies in connectivity, autonomous driving and artificial intelligence. Albemarle Corporation (NYSE: ALB) is the world’s largest lithium producer. The outlook for lithium demand is predicated upon increased demand for electric vehicle batteries. Lithium is used in electric vehicle batteries and many other electric-based solutions. As the demand for clean energy solutions increases, Albemarle’s lithium demand could increase as well. General Motors Company (NYSE: GM) makes electric vehicles, but isn’t considered an electric vehicle company just yet. Although the automotive giant’s electric vehicle lineup may not be seen as being on par with Tesla’s right now, the company has many resources and talent at its disposal to gain a strong footing in the EV industry. In fact, the company has committed to offering only electric vehicles by 2035. As more and more companies continue to shift to electric vehicles, it might be harder for Tesla to maintain its current status once EV options are more plentiful. See more from BenzingaClick here for options trades from BenzingaPete Najarian Sees Unusual Options Activity In Walgreens16 Stocks Moving In Thursday’s After-Hours Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
(Bloomberg) — Federal Reserve Bank of Minneapolis President Neel Kashkari on Monday became the latest central bank official to push back against the idea that the trading frenzy in GameStop Corp. and other hot stocks calls for a monetary policy response.“GameStop has gotten a lot of attention. If one group of speculators wants to have a battle of wills with another group of speculators over an individual stock, God bless them,” Kashkari said while answering questions during a virtual town hall event.“That’s for them to do, and if they make money, fine. And if they lose money, that’s on them,” he said. “I’m not at all thinking about modifying my views on monetary policy because of speculators in these individual stocks.”GameStop shares were lower on Monday after rallying 1,600% in January. Hordes of day traders piled into the shares after noticing elevated short interest in the company in hopes that buying would force shorts to cover, driving the price ever higher.Kashkari’s perspective on the potential for froth in financial markets echoed that of some other Fed officials. At a Jan. 27 press conference, Chair Jerome Powell declined to comment on the recent meteoric rise in of GameStop shares and those of similarly beaten-down companies. But he told reporters that the main forces propelling the stock market higher in recent months were vaccine developments and fiscal stimulus.San Francisco Fed President Mary Daly chimed in on Jan. 29, arguing during a virtual event that she didn’t favor tightening up monetary policy, which would potentially slow the economic recovery, “simply to ensure that some people who already have stock market wealth don’t get more.”The U.S. central bank has signaled it will hold interest rates near zero at least through 2023 and keep buying bonds at a $120 billion monthly pace until “substantial further progress” has been made on employment and inflation.“The key now is for the Federal Reserve to keep our foot on the monetary policy gas until we really have achieved maximum employment,” Kashkari said.Speaking at a separate event Monday, Dallas Fed President Robert Kaplan said that while supervisors had good visibility on the capital levels of big banks through stress-testing as they gauge the potential for systemic risks, he was monitoring the situation closely.“Non-bank financials I’m watching very carefully — potential instability funding risks that might occur,” Kaplan said. “And I’m conscious of the fact that we’ve had to make these extraordinary moves that we’ve had at the Fed with interest rates and bond buying.”(Updates with Kaplan comments beginning in final paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Elon Musk spontaneously interviewed Robinhood CEO Vlad Tenev late Sunday evening, injecting himself into the fray of the retail investing frenzy that’s sent markets into a tailspin.
Members of the r/WallStreetBets Reddit community that’s taken Wall Street by storm discuss the GameStop frenzy and what drove them to scoop up shares.
Nio is growing its lineup of electric vehicles as sales boom for the emerging Tesla of China. But is Nio stock a buy right now?
Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.
Investors on Monday place more than $33 billion worth of orders into Apple Inc.’s new $14 billion debt deal, which the company says partially could be used to buy back stock and fund dividend payments.
Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of January 25th – 31st, 2021. Without further ado, let’s get started. * Yahoo Finance readers, please click here to view the full article. 10. Red White & Bloom and High Times Respond to Soaring Cannabis Demand in Michigan RWB’s Second High Times Release Will Be Available in Twice the Number of Dispensaries as the December Launch and Feature Three New Unique Strains: Red White & Bloom (OTCQX: RWBYF) announced on Wednesday, the second release of its exclusive line of High Times branded cannabis products in Michigan. The company’s quick follow-up release is in response to soaring cannabis demand in Michigan after last month’s initial launch sold out in just hours. READ FULL RWB ARTICLE 9. First Psychedelics ETF Debuts on NEO Exchange PSYK is the First Exchange-Traded Fund (ETF) Providing Exposure to the Burgeoning Industry of Medicinal Psychedelics The Horizons Psychedelic Stock Index ETF (NEO: PSYK) is now listed on Toronto’s NEO Exchange (NEO) under the symbol ‘PSYK.’ The ETF is managed by Horizons ETFs Management, a Canadian ETF firm that’s part of the portfolio of Mirae Assets. In 2017, Horizons released the Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ) (OTC: HMLSF), the cannabis sector’s longest-running ETF. The Psychedelics ETF’s is currently made up of 17 top Psychedelic Stocks, which include big names such as Compass Pathways (NASDAQ: CMPS), MindMed (OTCQB: MMEDF), Field Trip Health (OTC: FTRPF) and Johnson & Johnson (NYSE: JNJ). READ FULL PSYCHEDELICS ETF ARTICLE 8. Arizona Heats Up: Mint, Columbia Care, Curaleaf And Harvest Health Commence Recreational Weed Sales Arizona Welcomed Adult-Use Cannabis Legalization During November’s Election, and Some Three Months Later it Commenced With the Sales On Friday, the state-approved 73 applications out of 79 submitted, kicking off its adult-use Cannabis program. Out of 15 counties in Arizona, only nine had their dispensaries acquire the license for adult-use sales. The outlet projects for the state’s recreational market to reach between $375 – $400 million in the first year, and between $700 million and $760 million by 2024. Among large companies who already attained approval for recreational Marijuana sales in Arizona are The Mint Dispensary, Columbia Care (OTCQX: CCHWF), Curaleaf (OTCQX: CURLF) and Harvest Health (OTCQX: HRVSF). READ FULL ARIZONA CANNABIS ARTICLE 7. Aphria Partners With AMP Cannabis to Push German Cannabis Sales While Details Were Rather Slim Within the Release, it Appears That AMP Will Be Utilizing its Marketing Know-How to Push Aphria’s Brands Through its Network Aphria (NYSE: APHA) and AMP German Cannabis Group (CSE: XCX) issued a brief joint press release, outlining that the two firms have partnered up to push sales in Germany. The arrangement has seen the two firms enter a joint marketing agreement for the sale of Aphria branded medical Cannabis within the German market. READ FULL APHRIA ARTICLE 6. Field Trip Health Ltd. Announces the Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the U.S. The Field Trip Health Location in Atlanta is Believed to Be the First Psychedelic-Enhanced Therapy Center in the City Field Trip Health (OTC: FTRPF), a global leader in the development and delivery of Psychedelic therapies, announced today the opening of their fifth location in the United States in the city of Atlanta, GA, one of many locations that Field Trip is planning to open in 2021. Located in the Glenwood Park neighborhood, the Atlanta location is the first Field Trip Health center to open this year, following the opening of Toronto, New York, Los Angeles and Chicago in 2020. READ FULL FIELD TRIP ARTICLE 5. Tilray Selected To Supply Medical Cannabis For French Experimental Program The First Products Are Expected to Be Delivered Within the First Quarter of 2021 Tilray (NASDAQ: TLRY) has expanded its international operations to now include France. The company this morning revealed that it was selected by the French National Agency for the Safety of Medicines and Health Products to supply medical cannabis for experimentation in France. Tilray currently intends to export medical Cannabis from its facility in Portugal, with the necessary permits already having been received. READ FULL TILRAY ARTICLE 4. Mydecine Innovations Group Files for Application to List on NASDAQ Denver-Based Biopharma and Life Sciences Company, Mydecine Innovations Group Has Announced Their Formal Application to List on the NASDAQ Stock Exchange After their recent inclusion in the new Horizons Psychedelic Stock Index ETF (NEO: PSYK), Mydecine Innovations (OTC: MYCOF) is following in the footsteps of Psychedelic compatriot MindMed (OTCQB: MMEDF), who submitted its uplisting to the NASDAQ in September 2020. Along with the psychedelic pharmaceutical giants Compass Pathways (NASDAQ: CMPS) and MindMed (which applied in late Q3 2020), Mydecine also plans to file a Form 20-F with the SEC in due course. They will also be joined by private psychedelic investment vehicle ATAI Life Sciences in the Spring. READ FULL MYDECINE ARTICLE 3. Here’s Why the Creso Pharma Share Price is Rocketing Higher Creso Pharma’s Stock Started the Week With a Bang Investors have been buying Creso Pharma (OTC: COPHF) shares following the release of an announcement in relation to over-the-counter sales of low-dose cannabidiol (CBD) products in Australian pharmacies. According to the release, Creso Pharma expects to benefit from changes in legislation that mean low-dose CBD products can be sold over-the-counter in Australian pharmacies from this morning. READ FULL CRESO PHARMA ARTICLE 2. Why Magic Mushroom Stocks Are 2021’s New Pot Stocks Although Psilocybin Aka Magic Mushrooms Are Still Mostly Illegal in the U.S. and Other Countries, Research Has Shown the Drug’s Effectiveness at Treating Conditions Such as Depression, Anxiety, and Opioid Addiction It’s not news that Pot Stocks gave investors some sweet returns in 2020, but not everyone got to the party on time. If you feel like you missed the boat on the Cannabis Boom. There might be an exciting new investment opportunity in the world of medicinal drugs in form of Psychedelic Stocks. READ FULL SHROOM STOCKS ARTICLE 1. Under Joe Biden, Cannabis Stocks Will Have A “GameStop Moment”— Just Like They Have Before What Does Joe Biden as President Mean for Cannabis Businesses? Well, Nothing, Reall Joe Biden didn’t promise to legalize marijuana while campaigning, But Biden is a Democrat, and there are a lot of Democrats who are pro-marijuana. Since investors “know” cannabis legalization is coming, and since that means cannabis is a “good investment,” investors go out and buy some of the only cannabis securities available to them. This trend suggests that r/wallstreetbets or another online forum could easily target a cannabis company as a buy target and inflate its value. Like GameStop Corp. (NYSE: GME), with that company doing absolutely nothing to necessarily deserve an enormous rise in value. READ FULL CANNABIS STOCKS ARTICLE Photo by Matteo Paganelli on Unsplash See more from BenzingaClick here for options trades from BenzingaCannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The WeekCannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
– Global Natural Gas Treatment Sales Market 2020 Growth Statistics, New Opportunities, Competitive Outlook and …
– Global Blood Transfer Bags Market is to Witness Significant Growth between 2020-2026 with leading players TERUMO …
– Global Milling Tools Market Report: Production, Revenue, Price Trend by Types & Market Analysis by Application
– Meat Cutter Machine Market Overview and Competitive Landscape 2021 to 2026| FAM, Cheersonic, GEA Group …
– Global Cold Milling Machine Market Outlook Report 2020 – Growing Focus Towards the Development of New Roads …
– Detailed Overview of Cylindrical Milling Cutter Market 2020-2026 by Adolf Wurth GmbH & Co. KG, ALPEN …
– Bench Milling Machine Market 2021 Global Insights and Business Scenario – 600 Group, ANG International, CAMAM …
– Milling Machine Market Size 2019, Market Opportunities, Share Analysis Up To 2026
– Global Milling Machine Industry Analysis by Manufacturers, Production Capacity, Market Share, Price, Mergers …
– Global Open-Side Milling Machine Market 2021 Future Growth Explored in Latest Research Report by 2027, key …